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Plasma volume expansion in patients with heart failure (HF) is asso-
ciated with neurohumeral activation; symptom and signs of pul-
monary congestion and peripheral oedema; an increase in
hospitalizations for HF; and cardiovascular mortality.1 A reduction
in plasma volume, as evidenced by haemoconcentration, has
recently been suggested to be associated with an improvement
in cardiovascular mortality.2 However, while loop diuretics
reduce plasma volume and relieve the symptoms and signs of pul-
monary congestion, they activate the renin–angiotensin–aldoster-
one system (RAAS) and, in experimental studies3 and some,
although not all, retrospective clinical studies have been associated
with an increase in cardiovascular mortality.4,5 Due to the contro-
versy associated with the use of high-dose loop diuretics and their
effect on cardiovascular mortality in patients with HF and a
reduced left ventricular ejection fraction (REF) there has been in-
creasing interest in alternative and or supplemental diuretic strat-
egies to reduce plasma volume and to improve cardiovascular
outcomes in patients with HFREF.
Tolvaptan, a selective V2 vasopressin antagonist, has been
shown in pre-clinical and short-term studies in patients with
HF to be a potent aquaretic with a resultant increase in urine
output; a decrease in body weight; a decrease in pulmonary ca-
pillary wedge pressure; an increase in serum sodium concentra-
tion; without activation of the RAAS.6 However when studied
over the longer term in patients with HFREF, it has not been
shown to reduce natriuretic peptide levels or left ventricular re-
modelling,7,8 and did not improve cardiovascular outcomes
despite an early improvement in symptoms of dyspnoea, a pro-
longed reduction in body weight, and normalization of serum
sodium in hyponatraemic patients.8,9 The finding that tolvaptan
failed to reduce natriuretic peptide levels and cardiovascular out-
comes despite a reduction in body weight is especially notable
since an increase in body weight post-discharge is the single
most important predictor for readmission in patients with
heart failure and a major predictor of mortality.10 The explan-
ation for the failure of tolvaptan to improve ventricular remod-
elling, natriuretic peptide levels, and cardiovascular outcomes
despite a reduction in body weight remains uncertain. Several
explanations have, however, been proposed, including the sug-
gestion that the dose of tolvaptan (30 mg/day) may have been
inadequate; that patients selected for study did not have hypona-
traemia; and the possibility that a reactive increase in vasopressin
levels might over the long term stimulate the V1a receptor with
a resultant increase in vasoconstriction, which might negate the
beneficial effects associated with aquareses.6,11 Without further
prospective mechanistic studies it is difficult to confirm or
refute these explanations. Recently, however, it has been
shown that a deficiency of the V1a receptor causes hyporeninae-
mic hypoaldsteronism,12 and stimulation of the V1a receptor
causes the adrenal production of aldosterone.13 The V1a recep-
tor also affects the renal tubular effects of aldosterone.14 We
postulate that these findings may explain the paradox of a per-
sistent reduction in body weight despite the lack of an improve-
ment in natriuretic peptide levels and cardiovascular outcomes
associated with the use of tolvaptan in EVEREST.11 This hypoth-
eses and its implications for the therapy of patients with HF will
be briefly discussed below.
As noted above, V2 receptor antagonism results in a sustained
reduction in body weight along with an early transient decrease
in pulmonary capillary wedge pressure15 without activation of
the RAAS.16 However, over the long term there is a reactive
increase in vasopressin levels,6,17 with a resultant increased
activation of the unprotected V1a receptor in the myocardium
and vascular wall. This increase in vasopressin levels in patients
receiving tolvaptan has recently been associated with an increase
in aldosterone levels.17
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In patients with HF there is an up-regulation of the mineralocor-
ticoid receptor (MR) in the myocardium18 and macrophages,19
along with an increase in plasma aldosterone levels.20 Aldosterone
and activation of the MR decrease antioxidant reserves, increase
reactive oxygen species (ROS),21 increase inflammatory cytokine
activation,22 increase tissue angiotensin-converting enzyme (ACE)
and angiotensin type 1 receptor (AT1R) expression,23 increase
the levels of plasminogen activator-1 (PAI-1) levels,24 stimulate
reactive myocardial and perivascular fibrosis, decrease nitric
oxide availability, increase endothelial dysfunction, increase
myocardial cell death, and reduce endothelial progenitor cell
production and vascular repair.25 Thus it can be postulated that
over the long term the beneficial effects of V2 receptor antagon-
ism may be negated by V1a receptor stimulation with subsequent
production of aldosterone, MR activation, sodium retention, and a
tendency to increase plasma volume which could offset the reduc-
tion in plasma volume resulting from blockade of the V2 receptor
and aquareses.
There are several implications of our hypotheses both for the
further evaluation of vasopressin antagonists and for the therapy
of patients with HF. The combination of a V2 receptor antagonist
and an MR antagonist (MRA) might be of interest especially in
patients with acute decompensated HF (ADHF). The current
dose of the MRAs spironolactone 25–50 mg and eplerenone
25–50 mg, while effective in reducing total mortality and hospita-
lizations in patients with chronic HFREF,26 are only mildly diuretic.
Prior to the RALES study,27 a dose of spironolactone 100–200 mg
day was suggested to be beneficial in overcoming diuretic resist-
ance in patients with ADHF.28 The increased levels of aldosterone
in patients receiving a V2 receptor antagonist might require these
higher doses of MRAs to block the MR and to achieve diuresis. The
combination of a V2 receptor selective antagonist and a high dose
MRA could provide an increase in urinary output, an increase in
sodium excretion, and a decrease in plasma volume, while prevent-
ing the activation of the MR with its adverse consequences. The
safety of this approach will, however, require prospective evalu-
ation. One might also consider the combination of a V2 receptor
selective antagonist with a natriuretic peptide. For example,
Costello-Boerrrigter et al.29 have shown that tolvaptan alone
increases systemic vascular resistance, blood pressure, and aldos-
terone levels. However, with the combination of tolvaptan plus
brain natriuretic peptide (BNP) there is no increase in systemic
vascular resistance, blood pressure, or aldosterone levels but an
increase in urinary sodium excretion. Conversely, one might con-
sider the use of a non-selective V1–V2 vasopressin receptor antag-
onist alone, which would not be expected to increase aldosterone
levels above the level associated with the severity of heart failure.
However, in view of the increase in aldosterone levels in patients
with HF independent of the long-term use of a V2 receptor
antagonist, it might be useful to consider a combination of a
non-selective V1–V2 antagonist in conjunction with an MRA or
natriuretic peptide such as BNP. Clearly, although the selective
V2 receptor antagonist tolvaptan has not been shown to reduce
cardiovascular outcomes in patients with heart failure,8 further
investigation of the combination of a V2 receptor antagonist and
an MRA or natriuretic peptide such as BNP and.or the use of a
non-selective V1–2 receptor antagonist alone or in conjunction
with an MRA or natriuretic peptide holds the promise of a reduc-
tion in cardiovascular outcomes in patients with acute and chronic
heart failure.
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